#USA #New York #Levi & Korsinsky #Securities Fraud #aTyr Pharma

Levi & Korsinsky Files Class Action on Behalf of aTyr Pharma Shareholders

In a significant development for investors of aTyr Pharma, Inc. (NASDAQ: ATYR), law firm Levi & Korsinsky, LLP has filed a class action securities lawsuit. The action aims to represent investors who are believed to have incurred losses due to alleged fraudulent activities by the company.

Overview of the Lawsuit

The class action is directed towards shareholders who were impacted by aTyr Pharma's purported securities fraud, taking place between November 7, 2024, and September 12, 2025. Levi & Korsinsky is notifying affected investors to ensure they have an opportunity to seek justice for their financial losses.

According to the complaint, aTyr Pharma's executives made overly optimistic statements regarding the efficacy of their drug, Efzofitimod. The lawsuit alleges that they misled investors by failing to disclose critical adverse facts about the drug's capabilities, particularly concerning its potential to enable patients to taper off steroid usage entirely.

Details of the Allegations

The issues escalated on September 15, 2025, when aTyr held an investor call that revealed disappointing results from the EFZO-FIT study. The company announced that the study did not achieve its primary endpoint, notably in the reduction of daily oral steroid doses. This revelation led to a dramatic decline in the stock price, dropping from $6.03 per share to $1.02 within a single day — a staggering 83.2% decrease.

Impact on Shareholders

This plunge in share price highlights the detrimental impact of the alleged securities fraud on investors. Those who suffered losses during the specified time frame are being encouraged to reach out to Levi & Korsinsky. The law firm urges affected shareholders to take action by December 8, 2025, to be appointed as lead plaintiff in the case.

No Costs for Participation

Levi & Korsinsky emphasizes that shareholders wishing to partake in the class action can do so at no cost. All legal fees and expenses related to the lawsuit will be covered for class members, making it an accessible option for those asserting claims against aTyr Pharma.

Why Choose Levi & Korsinsky?

With a successful track record spanning over 20 years, Levi & Korsinsky is recognized as one of the leading law firms in securities litigation. The firm has secured hundreds of millions of dollars for shareholders and is listed among the top firms in Securities Class Action Services' reports. Their experienced team, consisting of over 70 professionals, is prepared to combat the complexities of securities litigation on behalf of investors.

Conclusion

The initiation of this class action lawsuit serves as a critical reminder for investors to be vigilant regarding their rights in such situations. Shareholders of aTyr Pharma should not miss this chance to potentially recover their losses—taking swift action is essential. For further information or to register for participation in the lawsuit, affected shareholders can contact Levi & Korsinsky directly via phone or email.

• ---

Contact Information:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500